IP Library Patent Application 11034505
Patent Application
App. No. 11/034,505

Profiles of lipid proteins and inhibiting HMG-CoA reductase

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/034,505
Abstract

The present invention comprises methods and compositions for improving profiles of lipid proteins, reducing low-density lipoprotein levels, increasing high-density lipoprotein levels, decreasing the absorption of fatty acids across the intestinal epithelium and inhibiting HMG-CoA Reductase in living organisms utilizing Morinda citrifolia L activity in mammals, including humans.

Claims (19)

1 . A formulation adapted for improving lipoprotein profiles in mammals comprising: at least one processed Morinda citrifolia product present in an amount by weight between about 0.1 and 99 percent.

2 . The formulation of claim 1 , wherein said Morinda citrifolia product is used with a carrier medium.

3 . The formulation of claim 1 , wherein said processed Morinda citrifolia product comprises a processed Morinda citrifolia selected from a group consisting of: extract from the leaves of Morinda citrifolia , leaf hot water extract present in an amount by weight between about 0.1 and 50 percent, processed Morinda citrifolia leaf ethanol extract present in an amount by weight between about 0.1 and 50 percent, processed Morinda citrifolia leaf steam distillation extract present in an amount by weight between about 0.1 and 50 percent, Morinda citrifolia fruit juice, Morinda citrifolia extract, Morinda citrifolia dietary fiber, Morinda citrifolia puree juice, Morinda citrifolia puree, Morinda citrifolia fruit juice concentrate, Morinda citrifolia puree juice concentrate, freeze concentrated Morinda citrifolia fruit juice, and evaporated concentration of Morinda citrifolia fruit juice.

4 . The formulation of claim 1 , comprising at least one active ingredient selected from a group consisting of quercetin, rutin, scopoletin, octoanoic acid, potassium, vitamin C, terpenoids, alkaloids, anthraquinones, nordamnacanthal, morindone, rubiandin, B-sitosterol, carotene, vitamin A, flavone glycosides, linoleic acid, Alizarin, amino acids, acubin, L-asperuloside, caproic acid, caprylic acid, ursolic acid, and putative proxeronines.

5 . The formulation of claim 1 , wherein said formulation is administered to a patient by at least one method selected from a list consisting of orally, intravenously, and systemically.

6 . The formulation of claim 1 , further comprising at least one other ingredient selected from the group consisting of processed Morinda citrifolia products, food supplements, dietary supplements, other fruit juices, other natural ingredients, natural flavorings, artificial flavorings, natural sweeteners, artificial sweeteners, natural coloring, and artificial coloring.

7 . A formulation comprising:

at least one processed Morinda citrifolia product present in an amount by weight between about 0.1 and 99 percent, wherein the formulation is adapted to affect mammals in a way selected from a group consisting of: inhibit HMG-CoA Reductase, reduce low-density lipoprotein levels, increase high-density lipoprotein levels, protect by prophylactic treatment from tobacco smoke-induced cardiac disease, and decrease the absorption of fatty acids across the intestinal epithelium.

8 . A method for improving lipoprotein profiles in mammals comprising the step of:

administering a formulation containing at least one processed Morinda citrifolia product present in an amount by weight between about 0.1 and 99 percent.

9 . The method of claim 8 , wherein two ounces of the formulation is administered twice daily.

10 . The method of claim 8 , wherein said Morinda citrifolia product is administered with a carrier medium.

11 . The method of claim 8 , wherein said processed Morinda citrifolia product comprises a processed Morinda citrifolia selected from a group consisting of: extract from the leaves of Morinda citrifolia , leaf hot water extract present in an amount by weight between about 0.1 and 50 percent, processed Morinda citrifolia leaf ethanol extract present in an amount by weight between about 0.1 and 50 percent, processed Morinda citrifolia leaf steam distillation extract present in an amount by weight between about 0.1 and 50 percent, Morinda citrifolia fruit juice, Morinda citrifolia extract, Morinda citrifolia dietary fiber, Morinda citrifolia puree juice, Morinda citrifolia puree, Morinda citrifolia fruit juice concentrate, Morinda citrifolia puree juice concentrate, freeze concentrated Morinda citrifolia fruit juice, and evaporated concentration of Morinda citrifolia fruit juice.

12 . The method of claim 8 , wherein the formulation comprises at least one active ingredient selected from a group consisting of quercetin, rutin, scopoletin, octoanoic acid, potassium, vitamin C, terpenoids, alkaloids, anthraquinones, nordamnacanthal, morindone, rubiandin, B-sitosterol, carotene, vitamin A, flavone glycosides, linoleic acid, Alizarin, amino acids, acubin, L-asperuloside, caproic acid, caprylic acid, ursolic acid, and putative proxeronines.

13 . The method of claim 8 , wherein the formulation further comprising at least one other ingredient selected from the group consisting of processed Morinda citrifolia products, food supplements, dietary supplements, other fruit juices, other natural ingredients, natural flavorings, artificial flavorings, natural sweeteners, artificial sweeteners, natural coloring, and artificial coloring.

14 . The method of claim 8 , further comprising the step of concurrently administering said formulation with another medication designed to improve lipoprotein profiles and its associated conditions, wherein said formulation increases the efficacy of said medication.

15 . The method of claim 8 , wherein said formulation is administered in an amount between about 1 teaspoon and 2 ounces at least twice daily on an empty stomach each day.

16 . A method of treating mammals comprising:

administering a formulation containing at least one processed Morinda citrifolia product present in an amount by weight between about 0.1 and 99 percent, wherein the formulation is adapted to affect mammals in a way selected from a group consisting of: inhibit HMG-CoA Reductase, reduce low-density lipoprotein levels, increase high-density lipoprotein levels, to protect by prophylactic treatment from tobacco smoke-induced cardiac disease, and decrease the absorption of fatty acids across the intestinal epithelium.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2007
From: MORINDA, INC.
To: TAHITIAN NONI INTERNATIONAL, INC.
Reel/Frame 018851/0222 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2005
From: PALU, AFA KEHAATI; JENSEN, CLAUDE JARAKAE; WANG, DR. MIAN YING; ZHOU, BING NAN; STORY, STEPHEN
To: MORINDA, INC.
Reel/Frame 016017/0583 →